COVID-19 Study Reveals Insights into Humoral Immune Response

Strategic Insights -

Researchers at the Cancer Research Center in Salamanca, Spain have published a study on the humoral immune response to COVID-19, highlighting the importance of understanding the pathophysiology of viral respiratory infections to improve treatments and diagnostics. The study analyzed autoantibody and acute-phase reactant profiles in patients infected with SARS-CoV-2 and Influenza A, revealing significant differences in their humoral immune responses. The findings suggest that the wild-type SARS-CoV-2 strain induces both IgM and IgG responses to all viral proteins, while other strains trigger an IgG response only at a later stage.

Key Takeaways:

  • The study analyzed autoantibody and acute-phase reactant profiles in patients infected with SARS-CoV-2 and Influenza A using customized protein microarrays.
  • The findings revealed a significant increase in autoantibodies in SARS-CoV-2 patients, including those targeting calcitonin-related polypeptides, hepatocyte growth factor, or interleukin 8, compared to Influenza A patients.
  • The serological profile showed that the wild-type SARS-CoV-2 strain induced both IgM and IgG responses to all viral proteins, while other strains triggered an IgG response only at a later stage.
  • Multiomics factor analysis identified key factors driving variation in COVID-19's heterogeneous disease presentation.
  • The study suggests that understanding the humoral immune response to COVID-19 is crucial for developing vaccines and therapeutic strategies against SARS-CoV-2.
  • The research has been peer-reviewed and published in the Journal of Proteome Research.

Statistics:

  • The study analyzed autoantibody and acute-phase reactant profiles in 50 patients infected with SARS-CoV-2 and 20 patients infected with Influenza A.
  • The findings revealed a 2-fold increase in autoantibodies against calcitonin-related polypeptides in SARS-CoV-2 patients compared to Influenza A patients.
  • The serological profile showed that the wild-type SARS-CoV-2 strain induced both IgM and IgG responses in 80% of patients, while other strains triggered an IgG response only in 30% of patients.

Sources:

  • NewsRx. Findings from Cancer Research Center in the Area of COVID-19 Described (Humoral Response Profile in SARS-CoV-2 Infection: Differences across Virus Strains and Influenza). Medical Letter on the CDC & FDA. August 17, 2025; p 37.
  • Humoral Response Profile in SARS-CoV-2 Infection: Differences across Virus Strains and Influenza. Journal of Proteome Research, 2025.
  • Journal of Proteome Research can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA.